Patient demographics
| No significant MR n=256 | Significant MR n=60 | p Value | |
|---|---|---|---|
| Age (years, mean±SD) | 81.8±8.9 | 83.2±7.4 | 0.288 |
| Male % (n) | 57.8% (148) | 55.0% (33) | 0.692 |
| Peripheral vascular disease | 11.3% (29) | 18.3% (11) | 0.142 |
| Chronic respiratory disease | 21.5% (55) | 23.4% (14) | 0.952 |
| Pulmonary hypertension | 19.0% (48) | 30.0% (18) | 0.060 |
| Prior revascularisation | 39.5% (101) | 41.7% (25) | 0.753 |
| Logistic EuroScore (%) | 20.3±10.7 | 28.7±16.6 | 0.004 |
| STS | 5.7±3.1 | 7.7±3.7 | <0.001 |
| New York Heart Association | |||
| Class I | 2.3% (6) | 5.0% (3) | 0.014 |
| Class II | 29.7% (76) | 21.1% (13) | |
| Class III | 60.5% (155) | 53.3% (32) | |
| Class IV | 7.4% (19) | 20.0% (12) | |
| LVEF (%) | 50.4±11.8 | 44.0±14.6 | 0.004 |
| Peak AV gradient (mm Hg) | 72.0±23.7 | 72.0±54.6 | 0.995 |
| Aortic valve area (cm2) | 0.68±0.24 | 0.69±0.30 | 0.749 |
| Aortic regurgitation ≥grade 3 | 12.1% (31) | 28.3% (16) | 0.046 |
| Tricuspid regurgitation ≥grade 3 | 9.0% (23) | 28.4% (17) | <0.001 |
| eGFR (mL/kg/1.73 m2) | 57.0±22.2 | 52.5±20.7 | 0.149 |
| Site | |||
| Transapical | 35.9% (92) | 36.7% (22) | 0.994 |
| Transfemoral | 45.7% (117) | 45.0% (27) | |
| Transaortic | 18.4% (47) | 18.3% (11) | |
eGFR, estimated glomerular filtration rate; MR, mitral regurgitation; STS, Society of Thoracic Surgeons.